We are a leading provider of GLP/GCP compliant accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Our customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance.

AMS is an ultrasensitive detection platform capable of quantifying 14C-labeled molecules in the 0.001-100 DPM/mL range. Accium launched the first commercial AMS facility in North America in early 2006. We offer the most sensitive AMS service available to the pharmaceutical industry. Our services are used by five of the top ten global pharmaceutical companies including Merck, Novartis and Bristol-Myers Squibb. 

Accium delivers its services through the AMS, Bioanalytical and Quality service units. Customers can mix and match services from any service unit in order to achieve the right outcome at the right cost. This efficient model enables Accium to offer the lowest cost AMS service available anywhere in the world. In addition, Accium's DirectAMS program makes AMS more accessible and more affordable than ever before. 

Welcome Julie Zalikowski! 
Director, Bioanalytical Services at Accium

Accium is pleased to announce the addition of Julie Zalikowski to Accium’s scientific team. Julie joined Accium in late 2012 bringing with her over 15 years of experience within the pharmaceutical bioanalytical industry, including leadership positions at Amgen, Novartis Diagnostics and AstraZeneca. You can read more about her here.

Absolute Bioavailability Studies by AMS
(Co-published with Merck)

"The CV and accuracy were 3.4-8.5% and 94-108% (82-119% for the lower limit of quantitation (LLOQ)), respectively, with a correlation coefficient of 0.9998....The precision and accuracy of quality controls and calibration standards met the requirements of bioanalytical guidance (FDA Guidance for Industry: Bioanalytical Method Validation, May 2001)."